文献速递类风湿关节炎

血清阴性类风湿关节炎的长期结局

Long-Term Outcomes in Seronegative Rheumatoid Arthritis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-03-15

该研究基于Olmsted County的176例血清阴性RA患者,评估10年内诊断变更、无药缓解及b/tsDMARD启动的累积发生率。10年诊断变更率为12.8%,无药缓解率为26.6%,b/tsDMARD启动率为19.9%。

要点

  • 血清阴性RA患者10年诊断变更累积发生率为12.8%,最常见变更为脊柱关节炎(4%)。
  • 10年无药缓解累积发生率为26.6%,中位随访11.8年间49人进入无药缓解。
  • 10年b/tsDMARD启动累积发生率为19.9%。

核心结论

  • 血清阴性RA初诊后约13%的患者在10年内诊断发生变更,约四分之一在10年内经历无药缓解。

研究设计与样本

  • 基于Olmsted County成年居民的手工病历回顾性队列研究,纳入符合1987和/或2010年ACR分类标准的血清阴性RA患者,数据收集自2005年1月1日至2023年12月31日。

主要发现

  • 共纳入176例血清阴性RA患者,其中女性占68%。
  • 10年诊断变更累积发生率为12.8%(95%CI 8.7%-18.9%),最常见变更为脊柱关节炎(4%)。
  • 10年无药缓解累积发生率为26.6%(95%CI 20.7%-34.2%)。
  • 10年b/tsDMARD启动累积发生率为19.9%(95%CI 14.7%-26.9%)。
  • 中位随访11.8年期间,49例患者进入无药缓解。

关键数值与推荐

  • 无药缓解定义为至少6个月未接受RA治疗且风湿科医生评估无活动性炎性关节炎证据。
  • 诊断变更累积发生率调整了死亡竞争风险;无药缓解和b/tsDMARD启动累积发生率调整了死亡或诊断变更的竞争风险。

临床怎么用

  • 原文未提供临床实践建议。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this study was to determine the cumulative incidence of diagnosis switching, drug-free remission, and initiation of a biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) in individuals with seronegative rheumatoid arthritis (RA). METHODS: Adult residents of Olmsted County, Minnesota, with incident seronegative (rheumatoid factor negative/anti-cyclic citrullinated peptide antibody negative) RA meeting the 1987 and/or 2010 American College of Rheumatology classification criteria were included. Data were collected from January 1, 2005, to December 31, 2023, through manual chart review. Drug-free remission was defined as a period of at least six months where the individual was no longer taking treatment for RA and did not have evidence of active inflammatory arthritis upon evaluation by a rheumatologist. We calculated the 10-year cumulative incidence of a change in diagnosis, adjusting for the competing risk of death, and of drug-free remission and initiation of a b/tsDMARD, adjusting for the competing risks of death or change in diagnosis. RESULTS: A total of 176 individuals with seronegative RA (68% women) were included. The 10-year cumulative incidence of a change in diagnosis was 12.8% (95% confidence interval [CI] 8.7%-18.9%). The most common change in diagnosis was to spondyloarthritis (4%). The 10-year cumulative incidence of drug-free remission and initiation of a b/tsDMARD was 26.6% (95% CI 20.7%-34.2%) and 19.9% (95% CI 14.7%-26.9%), respectively. Over a median follow-up of 11.8 years, 49 individuals entered drug-free remission. CONCLUSION: After initial diagnosis of seronegative RA, about 13% of individuals had a change in diagnosis and a quarter experienced drug-free remission within 10 years.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Kimbrough BA, George RJ, Crowson CS, et al. Long-Term Outcomes in Seronegative Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2026. PMID: 41386743. doi:10.1002/acr.70011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。